Latest:
Dr. Ramaswamy Discusses Tumor Heterogeneity
Dr. Sridhar Ramaswamy from the Massachusetts General Hospital Cancer Center Discusses Tumor Heterogeneity
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Stacey Shiovitz, MD
Latest:
Colorectal Cancer: Right Test, Right Time
Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease, with molecular features defining emerging subtypes. Understanding which tests to order in which cases can better direct care for our patients. Increasingly, panel testing has advantages over individual genetic testing.
Stacie Levine, MD
Latest:
Dr. Levine on Palliative Care for NSCLC
Stacie Levine, MD, associate professor of Medicine, director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, University of Chicago Medicine, discusses the benefits of palliative care for patients with non–small cell lung cancer (NSCLC).
Staff Writer
Latest:
Giants of Cancer Care® Announces the 11th Annual Class of Inductees
OncLive®, the nation’s leading multimedia resource for oncology professionals and Pfizer (platinum sponsor) and Exelixis and Stemline (gold sponsors), are pleased to announce the inductees of the 11th Annual Giants of Cancer Care recognition program.
Stanton R. Mehr
Latest:
Medicaid Expansion Plans Provide Novel Approaches for Healthcare Coverage
The US Supreme Court's decision to uphold the Affordable Care Act but allow states to decide whether to expand Medicaid has raised a question in many states: Where political leaders have been opposed or split on President Obama's healthcare reforms, is it smart or foolish to cover more people?
Stefani Spranger, PhD
Latest:
Stefani Spranger on the Role of CD8 T Cells in Melanoma
Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago Medicine, discusses how the presence or absence of CD8 T cells can affect treatment approaches for patients with melanoma.
Stephan Grupp, MD, PhD
Latest:
Dr. Grupp on the Optimal Setting of CAR T-Cell Therapy in ALL
Stephan Grupp, MD, PhD, director, Cancer Immunotherapy Program, director, Translational Research for the Center for Childhood Cancer Research, medical director, Stem Cell Laboratory, Children’s Hospital of Philadelphia, discusses the placement of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with acute lymphoblastic leukemia (ALL).
Stephanie A. Terezakis, MD
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis
Intensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.